Fructose oligosaccharides as novel cryoprotectants for mammalian cells

JULIE MENEGHEL; NELSON ROMANO; FERNANDA FONSECA; PETER KILBRIDE; JEROME DELETTRE; STEPHANIE PASSOT; AYELEN HUGO; ANDREA GÓMEZ-ZAVAGLIA

Chicago

Conferencia; 57va Reunión Anual de la Sociedad de Criobiología ? CRYO 2020; 2020

Sociedad de Criobiología

Mammalian somatic cells are widely cryopreserved, for preparation and delivery of cellular therapies; for laboratory logistics; and for quality control amongst a wide variety of reasons. The most commonly used cryoprotectant is dimethyl sulphoxide (DMSO). The cryoprotective abilities of DMSO were first recognized in the 1950s by Lovelock. DMSO protects cells through a variety of mechanisms including membrane stabilisation and diluting of high concentrations of solutes which can develop in intracellular channels during the cryopreservation process. There is demand, however, to develop new cryoprotectants which may be used alone or in conjunction with DMSO. New cryoprotectants may alleviate some toxicity concerns related to DMSO and allow for new cryopreservation strategies.In this study, we have examined the use of fructose-based oligosaccharides (FOS) as a cryoprotectant in a range of mammalian somatic cell types, finding that cryoprotection is given by FOS to Chinese Hamster Ovarian cells, Jurkat (immortalized t cell line), and CACO-2 (colorectal adherent) cells. Disparate cell types were specifically chosen to determine if FOS could be used more generally as a mammalian somatic cryoprotectant and was not cell specific. This agrees with previous research considering bacterial cells. The optimal concentration and composition of FOS was determined (10% w/v), as well as its interaction with other cryoprotectants such as sugars and DMSO.This work forms the basis of using FOS as a cryoprotectant for mammalian cells, and this group of sugars may prove a novel source of mammalian somatic cell cryopreservation.